ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis CEO Sees Big Potential In Biosimilars

ZURICH -(Dow Jones)- Novartis AG (NVS) Chief Executive Joe Jimenez said Tuesday he sees potential in the market for biosimilars, cheaper versions of expensive and complex medicines made from biological matter. "This is a market that is relatively small today, but we expect that by 2020 this could be a 15 to 20 billion dollars segment of the generics business," Jimenez told analysts in a call. "Novartis is uniquely positioned in biosimilars because we have the scientific and medical expertise of a pharmaceutical company and the commercial expertise of a generics company," he said. Novartis has its own generics unit, Sandoz. Biosimilars are imitations of biotech drugs, ones that are basically interchangeable with a previously approved biologic but because of the inherent complexity of the products cannot be termed identical. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
04/24/201417:35:36ADR Shares End Mixed; Unilever, AstraZeneca Shares Active
04/24/201415:35:42U.S. Stocks Rise, Buoyed by Apple Results
04/24/201415:20:17Lilly Says Takeda May Not Cover Its Share of $9 Billion Lawsuit
04/24/201412:39:32Novartis Leads Zurich Stocks Lower
04/24/201412:37:47EUROPE MARKETS: European Stocks End Choppy Day In Black
04/24/201410:39:52EUROPE MARKETS: European Stocks Pare Gains On Ukraine Tensions
04/24/201408:00:28Zimmer to Buy Biomet for $13.35 Billion -- Update
04/24/201406:18:32EUROPE MARKETS: European Stocks Strong After Ifo, Draghi Comments
04/24/201404:30:12Novartis 1Q Profit Rises About 23%
04/24/201402:40:06Novartis 1st Quarter Profit Rises About 23%
04/24/201402:27:06Novartis First-Quarter Profit Rises About 23% -- Update
04/22/201413:06:07LONDON MARKETS: Glaxo, AstraZeneca Lead U.K. Stocks To Two-week...
04/22/201412:38:25EUROPE MARKETS: Drug Stocks Drive European Markets Higher
04/22/201412:35:06Novartis 1Q 2014 -- Forecast
04/22/201409:50:05Glaxo Exits Cancer Drugs
04/22/201409:44:35LONDON MARKETS: Glaxo, AstraZeneca Lead Gains In U.K. Stocks
04/22/201409:34:59U.S. Stock Futures Trade Flat
04/22/201408:32:05Novartis Overhauls Portfolio With Deals Worth $25 Billion...
04/22/201405:51:23Novartis Overhauls Portfolio With Deals Worth $25 Billion...
04/22/201404:40:14European Stocks Start Strongly After Easter Holiday

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad